Qiagen: Challenging times but mid-term opportunities still compelling

BUY, Fair Value EUR17 (+13%)

News published on May Friday 3, 2013
Share on

While we acknowledge the market reaction following Q1 (guidance cut, Academia and Pharma weaknesses) and the Ingenuity acquisition (dilutive M&A and no news regarding shareholders’ return), we are still convinced of Qiagen’s growth potential. The Molecular Diagnostics franchise (50% of sales), including Personalized healthcare and QuantiFeron-TB, continues to grow at a steady double-digit growth rate (+11% CER in Q1). With the Ingenuity acquisition, we see increasing interest from investors towards Qiagen’s next generation sequencing offer to be launched in 2013. Therefore, we maintain our Buy rating.

Full report available to subscribers
Please contact marketing@bryangarnier.fr 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities